US8740602052 - ADR
TAKEDA PHARMACEUTIC-SP ADR
NYSE:TAK (5/17/2024, 7:04:00 PM)
13.22
-0.09 (-0.68%)
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 49,095 full-time employees. The firm is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The firm's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The firm is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
TAKEDA PHARMACEUTIC-SP ADR
4F, 2-1-1, Nihombashihon-cho
Chuo-Ku TOKYO-TO 103-8668
P: 81332782111
CEO: Christophe Weber
Employees: 49095
Website: https://www.takeda.com/
/CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a...
AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical.
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
Takeda Pharmaceutical just reported results for the fourth quarter of 2023.
Here you can normally see the latest stock twits on TAK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: